FDA OKs first generic version of Trileptal

Oct 10, 2007

The U.S. Food and Drug Administration announced approval of the first generic versions of the anti-convulsion drug Trileptal (oxcarbazepine).

The FDA said it approved generic oxcarbazepine for use alone or in combination with other medications in the treatment of partial seizures in adults and children aged 4 years and older.

Oxcarbazepine tablets in three strengths (150 milligrams, 300 milligrams and 600 milligrams) are manufactured by Roxane Laboratories Inc., Glenmark Pharmaceuticals Ltd. and Sun Pharmaceutical Industries Ltd.

According to the publication Drug Topics, Trileptal was the 74th best selling brand-name drug by retail dollars in the United States last year.

Copyright 2007 by United Press International

Explore further: High-dose opioid prescribing continues to climb

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments : 0